A breakthrough came with the development of selective CDK4/6 inhibitors, which have demonstrated efficacy in human luminal/estrogen receptor-positive cancer cells, suggesting their potential utility in breast cancer treatment56. Here, ESR1 is linked to breast carcinoma.